摘要
1975年至1989年作者共收治Ⅲ期胃窦、体部癌患者238例,随访90.7%,总5年生存率为45.4%,10年生存率为33.7%。扩大根治组(选择性R_3或R_3)术后5年和10年生存率分别为56.3%和47.5%,显著高于普通根治组(R_2)的35.7%和23.3%。术后辅助化疗组5年生存率和10年生存率分别为36.4%和12.1%。显著高于未用化疗组(9.5%和3.6%)。化疗加中药组术后生存率(78,1%和45%)显著高于单用化疗组。腹腔冲洗、化疗组和腹腔化疗组的腹膜转移率分别为18.7%和20.6%,显著低于腹腔未治疗组(31.9%)。作者认为Ⅲ期胃癌最佳治疗方案为切除足够的胃和淋巴结,防治腹膜和血行转移。
AbstractFrom 1975 to 1989,we treated 238 cases of gas-tric carcinoma in Ⅲ stage,90.7%of these were fol-lowed up, The total 5-year survival rate was 45.4%,10-vear survival 33.7%。The 5-vear survival rate and10-vear survival rate(56.3%and 47.5%)in the ex-tensive radical treatment group(102 cases , selectiveR_3 or R_3)was much higher than that of routine radicaltreatment group(114 cases R_2 ). The 5-year survivalrate and 10-year survival rate in the group with auxil-lary post-operational chemotherapy were much higherthan those of the group without chemotherapy. Thepost-operative survival rate in the group withchemotherapy plus Chinese medicine was much higherthan that of the group with chemotherapy alone, Theperitoneal metastatic rate of the group with peritonealflushing plus chemotherapy (18.7%and 20.6%)wasmuch longer than that of the group without peritonealflushing and/or chemotherapy (31.9%). We considerthat the best treatment of gastric carcinoma in Ⅲ stageis the sufficient removal of gastric lymph nodes for theprevention of metastasis through peritoneal and circu-latorv route.
出处
《中华外科杂志》
CAS
CSCD
北大核心
1995年第9期548-550,共3页
Chinese Journal of Surgery